About Bioline  All Journals  Testimonials  Membership  News

Indian Journal of Pharmacology
Medknow Publications on behalf of Indian Pharmacological Society
ISSN: 0253-7613
EISSN: 0253-7613
Vol. 36, No. 1, 2004, pp. 10-14
Bioline Code: ph04004
Full paper language: English
Document type: Research Article
Document available free of charge

Indian Journal of Pharmacology, Vol. 36, No. 1, 2004, pp. 10-14

 en Educational Forum - AntiTNF-α strategy: Present status of this therapeutic paradigm
J. Singh, A. Suruchi


Tumor necrosis factor-alpha (TNF-α), a proinflammatory cytokine is involved in the pathophysiology of a number of disorders including Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. AntiTNF-α strategies target this pathogenic element to provide clinical benefit. The various strategies are in preliminary stage of experimentation and much remains to be elucidated before these are applied clinically. Though antiTNF-α therapy is currently approved only for rheumatoid arthritis and Crohn's disease, the future of this therapeutic paradigm holds much promise. The number of official indications for strategies against this biologic agent are likely to increase to include congestive heart failure, psoriasis, asthma, septic shock, stroke and malignancy. This will make it a truly broad spectrum therapeutic weapon currently available to us.

AntiTNF-a therapy, etanercept, infliximab, tumor necrosis factor

© Copyright 2004 - Medknow Publications on behalf of the Indian Pharmacological Society. Also available online at
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil